PNC-27 dosage and protocol
Anti-cancer peptide designed to selectively bind to cancer cell membranes. Targets solid tumors without harming healthy cells.
- Vial size: 30 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 10 mg/mL
- Administration: intravenous
Research areas
- Cancer Targeting
- Tumor Destruction
- Experimental Therapy
Quick start
- Reconstitute: Add 3.0 mL bacteriostatic water to the 5 mg vial for about 1.67 mg/mL
- Typical dose: Not established; investigational use only
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL = 16.7 mcg on a U-100 syringe
- Storage: Refrigerate after reconstitution
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Preclinical/Early-phase | varies | IV or intratumoral | varies |
How it works
PNC-27 is a 32-amino-acid synthetic peptide combining a segment of the p53 tumour-suppressor protein's HDM-2-binding domain with a membrane-penetrating leader sequence. The proposed mechanism is that it binds HDM-2 (the human counterpart of MDM2) displayed on the outer membrane of many cancer cells, a location reportedly much less common in normal cells. This binding is thought to trigger formation of transmembrane pores, leading to rapid necrotic-type death of the cancer cell rather than classic apoptosis. In cell culture, PNC-27 killed a range of human cancer lines, including pancreatic, breast, leukaemia and melanoma cells, while sparing several normal cell types tested. Some mouse xenograft studies reported tumour growth inhibition. These findings come largely from a small number of laboratories. No completed, peer-reviewed human clinical trials have shown that PNC-27 is safe or effective for cancer. The claim that it harms no healthy cells rests on in vitro data and has not been established in living humans. It has been offered at some unregulated clinics, which carries serious risk if it delays proven cancer treatment.
Reconstitution steps
- Medical supervision required
- Follow clinical protocols
Storage
Store reconstituted peptide refrigerated. Investigational use only.
Important notes
- Synthetic peptide designed to selectively bind to cancer cell membranes via HDM-2 interaction
- Induces membrane disruption and apoptosis in tumor cells
- Shows promise in targeting solid tumors without harming healthy cells
- Still under investigation - immune responses and delivery methods are areas of focus
- Not approved for clinical use
- Novel and promising but investigational
Supplies
- Sterile water or bacteriostatic water
- Medical supervision required